Clinical Trial: A Study of Bometase Alfa for Bleeding Control in Acquired Hemophilia A

U.S., Aug. 28 -- ClinicalTrials.gov registry received information related to the study (NCT07789587) titled 'A Study of Bometase Alfa for Bleeding Control in Acquired Hemophilia A' on Aug. 24.

Brief Summary: This is a single-center, prospective, single-arm, exploratory study designed to evaluate the efficacy and safety of Bometase Alfa for the on-demand treatment of bleeding episodes in patients with acquired hemophilia A. A total of 20 patients with acquired hemophilia A experiencing bleeding events will be enrolled. Bometase Alfa will be administered at 0.1 U/kg for non-severe bleeding and 0.16 U/kg for severe bleeding, with consecutive doses given at 4-hour intervals until hemostasis is achieved. Treatment will be discontinued once hemo...